Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:20 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
NCT04221438 · ECOG-ACRIN Cancer Research Group · PHASE2 · terminated · last registry update 2026-10-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, ECOG-ACRIN Cancer Research Group |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Also stopped (suspended): National Cancer Institute (NCI), Mirdametinib + Sirolimus (NCT06876142)
- 2026-10-21Also stopped (terminated): Novartis Pharmaceuticals, JDQ443 + trametinib (NCT05358249)
- 2026-10-15Also stopped (suspended): City of Hope Medical Center, Dabrafenib + Trametinib (NCT03975231)
- 2026-10-06Also stopped (terminated): ECOG-ACRIN Cancer Research Group, Dabrafenib mesylate + Hydroxychloroquine (NCT04527549)
- 2026-09-14Phase 3 first posted: Carelon Research, Trametinib (NCT07817186)
- 2026-09-01Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Tazemetostat Hydrobromide (NCT04557956)
- 2026-08-24Results posted on the registry: Melanoma Institute Australia, Dabrafenib + Trametinib (NCT02858921)
- 2026-08-20Also stopped (terminated): SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, Mirdametinib 2mg + BGB-3245 5mg (NCT05580770)
- 2026-08-11Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Cobimetinib (NCT03600701)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-07-28Results posted on the registry: M.D. Anderson Cancer Center, Durvalumab + Selumetinib (NCT03581487)
- 2026-07-22Also stopped (terminated): M.D. Anderson Cancer Center, Everolimus + Neratinib (NCT03065387)
- 2026-06-10Results posted on the registry: Alliance for Clinical Trials in Oncology, Vemurafenib + Cobimetinib (NCT03224767)
- 2026-06-04Also stopped (terminated): Pfizer, PF-07284892 + lorlatinib (NCT04800822)
- 2026-05-27Results posted on the registry: Sarcoma Alliance for Research through Collaboration, Selumetinib + Sirolimus (NCT03433183)
- 2026-05-22Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT04940052)
- 2026-05-22Also stopped (withdrawn): University Health Network, Toronto, Trametinib tablet (NCT06098872)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Dabrafenib Mesylate + Trametinib Dimethyl Sulfoxide (NCT04439292)
- 2026-05-14Also stopped (terminated): University of Utah, Hydroxychloroquine + Trametinib (NCT03825289)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-08Also stopped (suspended): University of Chicago, VS-6766/avutometinib + Cetuximab (NCT05200442)
- 2026-05-04Results posted on the registry: Mayo Clinic, Atezolizumab + Cobimetinib (NCT03554083)
- 2026-05-01Results posted on the registry: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, Mirdametinib 2mg + BGB-3245 5mg (NCT05580770)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision